Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marker Therapeutics, Inc.

1.26
+0.01000.80%
Pre-market: 1.260.00000.00%07:07 EDT
Volume:28.40K
Turnover:35.75K
Market Cap:13.49M
PE:-1.05
High:1.30
Open:1.27
Low:1.21
Close:1.25
Loading ...

Company Profile

Company Name:
Marker Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
5
Office Location:
2450 Holcombe Blvd,MS: BCM251,Houston,Texas,United States
Zip Code:
77021
Fax:
- -
Introduction:
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Directors

Name
Position
Glynn Wilson
Chairman of the Board, Chief Executive Officer and President
David Laskow Pooley
Director
Frederick Wasserman
Director
Joshua Silverman
Director
Mark Reddish
Director
Sherry Grisewood
Director

Shareholders

Name
Position
Glynn Wilson
Chairman of the Board, Chief Executive Officer and President
Michael J. Loiacono
Chief Financial Officer and Chief Accounting Officer